The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.
Silver - Individuals: litigation
The IP group at Osborne Clarke received serious shots in the arm over the past 18 months – first with the arrival of new life sciences and healthcare head Will James in 2019, and then through the recruitment of former Bird & Bird pharmaceutical and biotechnology litigator Tim Harris in 2020. “Clear communicator and superb strategic leader” James has carried the day in court for the likes of Amgen, Genentech and AstraZeneca, and is “brilliant” at coordinating multi-jurisdictional patent litigation. Harris puts his Oxford chemistry qualifications to great use in assisting biotechnology players with their IP monetisation strategies; a facility for electronics inventions is another string to his bow. The pair join polished litigator Arty Rajendra, who concentrates on high technology and telecommunications; she made an indelible mark on the scene through her representation of Unwired Planet in its landmark Supreme Court FRAND licensing dispute against Huawei.
Will James advises in a wide range of technical industries: biotech, pharmaceutical, medical device, high-tech and electronics sectors. He has a special interest in artificial intelligence (AI) and in particular its applications in the technology and life sciences sectors.
Mr James’s practice covers three areas:
- strategic life sciences patent and product lifecycle advice;
- patent litigation in the UK courts and coordinating multi-jurisdictional teams in pan-EU enforcement and defence actions; and
- tech cases involving SEPs and FRAND issues.
The patents on which he has advised include core biotechnologies, particularly therapeutic antibodies, while on the tech side he has advised on electronic and GPS tagging patents, electronic program guides, RFID technology and air traffic control systems – involving SEPs, computer-implemented inventions and software issues.
Mr James advised the inventors on the first-ever successful employee inventor compensation claim in the UK courts and he continues to advise clients, both employer companies and employee inventors, in this area.
Mr James leads Osborne Clarke’s UK life sciences and healthcare sector; he sits on the IP Advisory Committee of the BioIndustry Association (BIA) and co-leads the BIA Subcommittee on AI.
IAM and clients say of him: “The practice kicked up a gear recently with the arrival of Will James, a dynamic litigator who can regularly be tracked down to the High Court.” “His advice is always pragmatic and commercially relevant, he is very responsive and he strives to provide the best service possible.”
Osborne Clarke is a future-focused international legal practice: across our well-connected network, we have over 900 talented lawyers and more than 270 expert partners based in 26 international locations* around the world. Our expertise in eight core sectors is focused on helping our clients to succeed in tomorrow’s world. Through our collaborative culture and sector-led approach, we have a robust understanding of the local business environment and in-depth legal expertise in each jurisdiction. We’re listeners, innovators and problem solvers, finding new ways to join the dots between our clients’ challenges today and the opportunities being created in an ever-evolving, ever-developing global society.
Our core sectors: life sciences and healthcare; media and comms tech; energy and utilities; financial services; real estate and infrastructure; workforce solutions; retail and consumer; and transport and automotive.
Osborne Clarke is the business name for an international legal practice and its associated businesses. Full details at www.osborneclarke.com/verein.
*Services in India are provided by a relationship firm.
Our IP practice
We pride ourselves in acting for clients for whom intellectual property is an important and valuable part of their business. Our all-round experience means we can help clients protect, manage, enforce and exploit their intellectual property.
Many of the world’s leading companies come to us for IP advice, whether that’s litigation to enforce their intellectual property or defend them against third parties, freedom to operate or protecting their portfolio of brands. We always advise in the context of our clients’ business and our sector experience underpins that.
We regularly work with global companies to devise the most effective pan-European IP strategies, and with offices in the six key European jurisdictions we can act locally to help you implement, exploit and enforce IP rights wherever appropriate.
Our patent specialists cover the full range of technologies with particular expertise in pharmaceuticals, biotechnology, medical devices, mobile telephony, electrical engineering, semiconductors and computer-implemented inventions.
We have helped leading technology companies manage and enforce their patent rights in the European Union. With specialists in the strategically important jurisdictions of the United Kingdom and Germany, we are on the spot in the cities where patent disputes are most likely to be fought. In all cases, we draw upon the technical and legal knowledge our lawyers have built up in this specialist area.
We also advise on the registrability of inventions in Europe, including appropriate and cost-effective strategies in the European Patent Office (EPO). We can also assist if you wish to license, acquire or dispose of patent rights, and assess a market opportunity. We have particular experience of FRAND licensing issues relating to standard-essential patents.
The practice is comprehensive in scope but is particularly known for acting in high-profile, high-value patent litigation, routinely involving an international element, as well as handling portfolio management matters for internationally recognised brands. We have acted in patent disputes in the English High Court, Court of Appeal, UK Supreme Court, EPO and UK Intellectual Property Office and the patent chambers of the courts in Dusseldorf, Munich, Hamburg, Manheim and Braunschweig, as well as the EPO and Federal Patent Court in cooperation with specialist external patent attorneys from the firm’s network.
We have extensive experience in a number of sectors including life sciences (eg, Amgen, Morphosys and the German Cancer Research Institute), telecoms/FRAND (eg, Unwired Planet and PanOptis), mechanical (eg, PopSockets, ARMOR, Deutsche Windtechnik) and electronics/media and communications (eg, Infobip), in part reflecting our sector strengths as a whole and underpinning how we can bring to bear a range of ancillary services to support our clients.
With high-profile cases such as advising on Unwired Planet v Huawei and acting in the Olanzapine and PCSK9 litigation, Osborne Clarke has demonstrated clearly its ability to operate at the highest level of the German, UK and international patent field. We do so through a team which has outgrown the scale of some of the firms already ranked by IAM Patent 1000.
Osborne Clarke is also advising on patent licensing and IP-related matters in high-profile transactions such as the acquisition of Flender from Siemens AG.